WELCOME TO THE
2025 MID-YEAR UPDATE
AIRED: Saturday, March 29, 2025 | 8:30 AM Pacific | Virtual Event
A Deep Dive Into PSMA, Spot Radiation, Genetic Testing, Biomarkers, and More.
Learn about prostate cancer, know your options, and get empowered.
WATCH BELOW!
CLICK THE VIDEO ABOVE TO WATCH THE CONFERENCE
SPEAKERS & AGENDA
MICHAEL STEINBERG, MD
Professor and is the Chair of the Department of Radiation Oncology in the David Geffen School of Medicine at UCLA
Topic: Spot Radiation & Advanced Prostate Cancer
TODD MORGAN, MD
Chief, Division of Urologic Oncology, Urology Jack Lapides M.D. Research Professor Professor, Urology
Topic: Genetic Testing & Biomarkers + Miscellaneous Q&A
EUEGENE KWON, MD
Professor of Urology and Immunology at the Mayo Clinic in Rochester, Minnesota
Topic: What I have learned after 10,000 PET-CT Scans: Part 1 and 2
MARK MOYAD, MD, MPH
Jenkins/Pokempner Director of Complementary and Alternative Medicine (CAM) Education at the University of Michigan Medical Center in the Department of Urology
Extended Q+A, Host & Moderator
MARK SCHOLZ, MD
Medical Director, Prostate Oncology Specialists | Founder & Executive Director, Prostate Cancer Research Institute
Extended Q+A & Host
AGENDA
SATURDAY, MARCH 29, 2025
8:30am - 8:35am / Opening Remarks / Alex Scholz
8:35am - 11:00am / Genetic Testing & Biomarkers / Todd Morgan, MD |
11:00am - 1:00pm / Spot Radiation & Advanced Prostate Cancer / Michael Steinberg, MD
1:00pm - 4:00pm / What I have learned after 10,000 PET-CT Scans: Part 1 and 2 / Eugene Kwon, MD
4:00pm - 5:30pm / 2025 Mid-Year Review & Extended Q+A / Mark Moyad, MD, MPH & Mark Scholz, MD
*Agenda subject to change
EXHIBIT HALL
Bayer is a global life sciences leader in healthcare and nutrition. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing therapies and delivering first-in-class educational and support programs to meet their needs.
This information has been reviewed according to the US law and is consistent with US Prescribing Information and is intended for US audience only. Prescribing Information may vary depending on local approval in each country.
Click here to learn more about Xofigo (radium Ra 223 dichloride)
Click here to learn more about NUBEQA (darolutamide)
For additional information, contact:
Rebecca Cowens-Alvarado, MPH
Deputy Director Advocacy Relations
Click here for Full Prescribing Information
PROVENGE
Prescribing Information:
https://www.provengehcp.com/Portals/5/Provenge-PI.pdf
Other Resources:
Provenge Support Information
https://www.provenge.com/Support
Your Provenge Experience:
CLICK HERE TO DOWNLOAD THE BROCHURE
PROSTOX genetic tests help prostate cancer patients choose the safest form of radiation treatment
These tests predict a patient’s risk of late, long-term side effects following two radiation treatment approaches for prostate cancer, based on the number of fractions a patient will receive:
PROSTOX ultra: for 5-7 fractions (sessions) given over 10 days, and called stereotactic body radiotherapy (SBRT)
PROSTOX CFRT: for 35-45 fractions (sessions) given over 8-10 weeks
Patient Information and Access
Find out if you’re eligible to access PROSTOX testing through MiraKind and learn more: https://mirakind.org/prostox-testing/
Clinical evidence and Information for physicians
PAN FOUNDATION
We help underinsured people with life-threatening, chronic and rare diseases get the medications and treatments they need by assisting with their out-of-pocket costs and advocating for improved access and affordability.
RESOURCES:
The PAN Foundation: https://www.panfoundation.org/
Our disease funds: https://www.panfoundation.org/find-disease-fund/
Find patient assistance in minutes! Sign up for FundFinder: https://fundfinder.panfoundation.org/
Become an advocate: https://www.panfoundation.org/become-an-advocate/
RSVP!
GET YOUR QUESTIONS
ANSWERED IN-PERSON IN LA!
2025 In-Person Prostate Cancer
PATIENTS & CAREGIVERS
Conference
SEPTEMBER 5-7, 2025
LOS ANGELES, CALIFORNIA
TICKETS ARE ONLY $30!
The 2025 Prostate Cancer Patient Conference is a three-day in-person educational event for prostate cancer patients and caregivers. Join other patients and caregivers in Los Angeles, CA, who will attend from the US and internationally. Renowned physicians from different specialties will be covering a wide variety of prostate cancer related topics. At the end of the conference, Mark Scholz, MD, and Mark Moyad, MD, MPH, host an extended Q+A session covering topics and questions that attendees have submitted.
LEARN ABOUT ALL THAT PCRI HAS TO OFFER
The PCRI provides resources for prostate cancer patients and caregivers looking to gain understanding, insight, and hope. Get honest answers from science based data.
Hello Researcher! We are the Prostate Cancer Research Institute (PCRI), a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for you. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call us at 1 (800) 641-7274 with any question that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
The PCRI 2024 Staging Guide breaks down the complex world of prostate cancer into five easy-to-understand color-coded stages: Sky, Teal, Azure, Indigo, and Royal. Each stage represents a unique situation based on PSA, Gleason score, and the extent of disease spread, helping men clearly understand their diagnosis and what treatments to consider. With clear visuals and simplified language, this guide empowers patients to have more informed conversations with their doctors and make decisions that match their personal goals and preferences.
SPEAKERS BIOGRAPHY
Professor and Chair of the Department of Radiation Oncology in the David Geffen School of Medicine at UCLA
Topic: Spot Radiation & Advanced Prostate Cancer
Biography: Dr. Michael Steinberg holds the academic rank of Professor and is the Chair of the Department of Radiation Oncology in the David Geffen School of Medicine at UCLA. He publishes and speaks on issues related to health policy, including delivery and quality of care, patient safety, evidence-based validation of emerging technology, healthcare economics, disparity, and value as well on a variety of clinical oncology topics. Dr. Steinberg's clinical focuses are prostate cancer, breast cancer, and head and neck cancer. He currently serves as Director of Clinical Affairs for the Jonsson Comprehensive Cancer Center at UCLA. He served as the PI for a National Cancer Institute Cancer Disparity Research grant ($3.5 million) and as a health services research investigator and manuscript author at the RAND Corporation.
Dr. Steinberg has been influential on a national level in providing input regarding health policy and economic issues on behalf of patients and his specialty through his various leadership roles. He is the founding Chair of the Health Policy Council of American Society for Radiation Oncology (ASTRO) and from 2010 to 2014, he was ASTRO's President and Chairman of the Board. In 2017, Dr. Steinberg received the ASTRO Gold Medal for his contributions to advancing patient care, research, and service to the specialty. Dr. Steinberg served for 8 years as the radiation oncology representative to the American Medical Association's CPT Editorial Panel and two terms on the CMS Medicare Evidence and Coverage Advisory Committee (MCAC). He is currently a member of the California Technical Assessment Forum, a public technology, and drug assessment organization that addresses comparative effectiveness of medical treatments.
Learn more about Dr. Steinberg here: https://www.uclahealth.org/providers/michael-steinberg
Chief, Division of Urologic Oncology, Urology Jack Lapides M.D. Research Professor Professor, Urology
Topic: Genetic Testing & Biomarkers + Q&A
Biography: Todd M. Morgan, M.D. is a urological surgeon and Chief of Urologic Oncology at Michigan Medicine. Dr. Morgan is originally from Seattle, WA and completed his undergraduate and medical training at Harvard University. He returned to the Northwest in 2003 for his urology residency at the University of Washington, before moving to Nashville for his fellowship training in urological oncology at Vanderbilt University. In addition to being a clinician and surgeon, Dr. Morgan is a translational surgeon-scientist. His research involves developing blood-based tests that can guide precision-based treatments for prostate cancer in real time, and he is principal investigator of two large randomized controlled trials evaluating tissue-based biomarkers in men with localized prostate cancer. Dr. Morgan has been the recipient of Young Investigator Awards from the Prostate Cancer Foundation, Society for Urological Oncology, National Comprehensive Cancer Network (NCCN), and Society for Basic Urology Research. He has served on a number of national guideline committees, such as the AUA Muscle-Invasive Bladder Cancer Guidelines, the AUA Advanced Prostate Cancer Guidelines, the NCCN Prostate Cancer Early Detection Guidelines, The ASCO Localized Prostate Cancer Guidelines, and the ASCO Molecular Markers for Prostate Cancer Guidelines.
Most importantly, Dr. Morgan is dedicated to caring for patients with genitourinary cancers. His urologic oncology practice includes caring for patients with prostate, bladder, kidney, and penile cancers, and his surgical expertise encompasses a wide spectrum of open, laparoscopic, and advanced robotic surgical approaches. He has substantial expertise in cancer genetics and the use and interpretation of molecular biomarkers, which can help guide individualized treatment choice for some patients.
Learn more about Dr. Morgan here: https://medresearch.umich.edu/profile/3567/todd-morgan
Professor of Urology and Immunology at the Mayo Clinic in Rochester, Minnesota
Topic: What I have learned after 10,000 PET-CT Scans: Part 1 and 2
Biography: Dr. Eugene D. Kwon is a full Professor of Urology and Immunology at the Mayo Clinic in Rochester, Minnesota. In addition, Dr. Kwon is the Director of Cancer Immunology and lmmunotherapy for the Mayo Comprehensive Cancer Center. Dr. Kwon also serves as the Vice-chair for the Mayo Clinic Institutional Review Board. Dr. Kwon received his undergraduate degree in Chemistry from Grinnell College and his M.D. degree from Rush Medical College in Chicago, Illinois. Dr. Kwon completed his urology resident training at the University of Iowa Hospitals and Clinics, while also completing an American Cancer Society sponsored fellowship in oncology. From 1992 until 1998, Dr. Kwon served as a National Research Service Award Postdoctoral Fellow within the Laboratory of Kidney Electrolyte and Metabolism at the National Heart, Lung and Blood Institutes at the NIH. During that time frame, Dr. Kwon also served as one of twelve research officers for the Special Research Officers Group of the Public Health Service.
Learn more about Dr. Kwon here: https://www.mayoclinic.org/biographies/kwon-eugene-d-m-d/bio-20054440
MEDICAL DIRECTOR, PROSTATE ONCOLOGY SPECIALISTS, INC., Marina del Rey, CA & EXECUTIVE DIRECTOR, PROSTATE CANCER RESEARCH INSTITUTE, Culver City, CA
TOPIC: Extended Q+A & Host
A double board-certified medical oncologist, Mark C. Scholz, MD, serves as executive director of the Prostate Cancer Research Institute (PCRI) and medical director of Prostate Oncology Specialists Inc. in Marina del Rey, CA, a medical practice exclusively focused on prostate cancer. He received his medical degree from Creighton University in Omaha, NE. Dr. Scholz completed his Internal Medicine internship and Medical Oncology fellowship at University of Southern California Medical Center.
Dr. Scholz is a strong advocate for patient empowerment. He is the co-author of the book Invasion of the Prostate Snatchers: No More Unnecessary Biopsies, Radical Treatment or Loss of Potency and the author of The Key to Prostate Cancer: 30 Experts Explain 15 Stages of Prostate Cancer. He has written and produced extensive educational material on the subject of prostate cancer in various media including DVDs, blogs, newsletters and pamphlets. He is an invited guest speaker at prostate cancer conferences and support groups throughout the world. He is also an educational speaker on behalf of Amgen, Dendreon and Sanofi-Aventis.
Dr. Scholz is at and co-founder of the Prostate Cancer Research Institute (PCRI), a non-profit organization dedicated to patient education and research. PCRI clinical research on the topic of hormone therapy has been published in the Journal of Urology, The Prostate, and UROLOGY. The PCRI also provides financial support for research endeavors in the area of active surveillance, prostate imaging, and the development of new tumor markers. Future directions for PCRI research are aimed at enhancing the anticancer function of the immune system, developing treatments to prevent bone metastases, and evaluating the impact of nutritional supplements.
Dr. Scholz served as oncology director at the Memorial Campus of the Centinela Freeman Regional Medical Center from 1996-2001. His current hospital affiliations include St. John’s Health Center, Marina del Rey Hospital. His society memberships include the American Society of Clinical Oncology, American Society of Therapeutic Radiology, American Urologic Associate and European Associate of Urology. He continues as a primary investigator actively supervising a number of ongoing prostate cancer clinical trials and has authored or coauthored over 90 scholarly articles and abstracts in his area of expertise.
Learn more about Dr. Scholz here: https://pcri.org/mark-scholz
Jenkins/Pokempner Director of Complementary and Alternative Medicine (CAM) Education at the University of Michigan Medical Center in the Department of Urology
Topic: Extended Q+A, Host & Moderator
Mark A. Moyad, MD, MPH, Dr. Moyad’s mission is to promote a greater attention to comprehensive lifestyle changes to improve overall mental, physical, and spiritual wellness along with contributing to more objective education on dietary supplements, OTC, and other potential health options. This has been the focus of his research, writings, and lectures his entire career. He occupies an endowed position, which was originally created and funded by the individuals he has empowered over the past 25+ years.
He is the Jenkins/Pokempner Director of Complementary and Alternative Medicine (CAM) Education at the University of Michigan Medical Center in the Department of Urology. This was one of the first endowments of its kind created for a doctor at a major medical center. Dr. Moyad has always considered himself to be first, and foremost, a public health educator with an expertise in clinical/medical epidemiology. Mark received his medical education from the University of South Florida College of Public Health and the Wayne State University School of Medicine. He is the primary author of over 150 medical journal publications on lifestyle changes and supplements, the past editor-in-chief of the medical journal Seminars in Preventive & Alternative Medicine, past CAM course director for a variety of medical societies, continues to be a guest editor and provide peer review for multiple medical journals, and he has given 1000s of lectures around the world to the public and health care professionals in virtually every medical specialty and major medical center. Mark is the author or co-author of 15 academic and consumer books, including his most recent updated 5th edition Promoting Wellness coming out late summer 2022. He now interviews other health experts on a variety of global wellness topics to enhance notable health care professional and patient education sources. He has provided educational clinical research updates for the last 20+ years to health care professionals and national patient advocacy groups. He has been a consultant and/or interviewed for most major magazines, websites, radio, and television shows devoted to health in the U.S. and appears regularly on a variety of network news/programs. Dr. Moyad also loves running, resistance exercise in moderation, artichokes, his wife Mia and kids, any University of Michigan Athletic team when they are winning, and their dog “Grazie”, but of course not in that specific order.
PS. He is also the moderator (for PCRI) of the largest patient conference in the world but hopes to relinquish this position one day soon in order to pursue his real passion and calling in life-being a part-time ESPN Sportscaster and a full-time international male model while simultaneously being further lionized by millions of fans with and without a prostate by becoming a world renowned bodybuilding champion (aka the next "Mr Olympia").
Dr. Moyad is a global expert in public health and education, offering approximately 35+ years of guidance to the public, healthcare professionals, and patient advocacy. He is now a full-time health educator. He does not see patients and is not able to respond to individual inquiries due to his ongoing educational roles with academia, PCRI, non-profits, and other health organizations and charities. As the moderator of the PCRI conferences for almost 20 years, Dr. Moyad regularly incorporates your questions from the PCRI Helpline into his discussions with leading experts who are best qualified to address them. For any questions regarding prostate cancer, you can contact the PCRI Helpline at: help@pcri.org
Learn more about Dr. Moyad here: https://pcri.org/mark-moyad
OUR SPONSORS
OUR ADVOCACY PARTNERS
A special thank you to all of our incredible advocacy partners!
We encourage all prostate cancer patients and their care-partners to explore the incredible resources provided by the other advocacy groups we've listed below. These organizations offer invaluable support, information, and community that can make a significant difference in your journey. The Prostate Cancer Research Institute deeply appreciates the remarkable work of these groups and extends our heartfelt thanks to them for their dedication and contributions. Your involvement with these groups can provide additional strength and guidance, enhancing your path to better health.
